noninvasive
accurate
safe
easy-to-use
inexpensive
CorAlert is testing its Beta model in multi-centered clinical trial, currently the trial has begun at a center in Israel and soon a second center in the US will open. The trial compares LVEDP measured by an invasive method (the insertion of a fluid filled catheter to the left ventricle during cathetarization) to LVEDP measured by the CA3.1 minutes prior to the invasive procedure. The results thus far have been very promising - a correlation greater than 0.9 with a P value less than 0.00013
The term "heart failure" (HF) doesn't mean that your heart has stopped or is about to stop working. Heart failure is a condition in which the heart can't pump enough blood to meet the body's needs. The causes of heart failure include ischemic heart disease, diabetes, high blood pressure, and other conditions or diseases. HF is a serious condition that requires medical care.
Over time, the heart weakens and isn’t able to fill with or pump blood as well as it should. As the heart weakens, certain proteins and substances may be released into the blood, which have a toxic effect on the heart and blood flow -- and worsen HF.
The detection of congestion in patients suffering from heart failure is crucial and can reduce the number of hospitalizations considerably. Changes in LVEDP suggesting an impending exacerbation of the condition of the patient that may lead to hospitalization occur before changes in other symptoms such as impedance or weight. Early detection of such changes will allow physicians the opportunity to adjust treatment and influence decision making in a manner which will improve patient outcome. CorAlert's CA3.1 is able to detect changes in Left Ventricular End Diastolic Pressure (LVEDP) in an easy-to-use, noninvasive way, at point of care.
Left Ventricular End Diastolic Pressure (LVEDP), or filling pressure, is the pressure in the left ventricle after it has rested and filled with blood -- and just before it begins a new contraction. LVEDP is a recognized predictor of hospitalization related to heart failure (HF). Up to now, unfortunately, it can only be measured by invasive methods.
The ability to measure LVEDP both in the hospital and at home will dramatically transform the management of HF, improving quality of life and survival rates
Software engineer & algorithm developer
team leader
Professor of cardiology, Bar-Ilan University, Former Head of Cardiology Sieff Medical Center
Owner and Investor - Endimo Group
and Prodac Systems
Owner - Micro BVM Ltd., develops and produces emergency medical devices
CorAlert had the pleasure to participate in the International Advanced Medical Technology Innovation Summit
Amir our CEO presented our technology in the road show
CorAlert was chosen as on of 500 companies ot of 3,500 applicants to attend the Hello Tomorrow Deep Tech Global Challenge Summit
CorAlert was also chosen as one of a 100 companies to present their technology during the Summit in a booth
Amir our CEO and Gal our VP Biz-Dev showing our device in the impressive Giant Health Event
CorAlert won along with 11 other israeli start-ups the Iot acceleration lab challenge
We had the amazing opportunity to set up a booth in the incredible CEATEC exhbition in Makuhari Messe
CorAlert had the pleasure to participate in the 1st Israel-Hunan matchmaking summit
Amir our CEO presented our technology in the road show
CorAlert develops noninvasive devices and systems for monitoring cardiovascular conditions, particularly those causing a significant clinical and economic burden to the health care systems
